Study details
Enrolling now
Mutant KRAS Peptide Vaccine Trial
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT IDNCT05013216ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
37
Study length
about 9.1 years
Ages
40+
Locations
1 site in MD
What this study is about
Researchers are testing a new vaccine, called mutant-KRAS peptide vaccine with poly-ICLC adjuvant, to see if it can help people at high risk of developing pancreatic cancer. The trial will evaluate the safety and how well the immune system responds to this treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cohort A: Patients at high risk of developing pancreatic cancer
- 2.Take Cohort B: Patients must have evidence of a pancreatic cystic neoplasm
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Oncology